C4X Discovery Holdings PLC
LSE:C4XD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
C4X Discovery Holdings PLC
Other Items
C4X Discovery Holdings PLC
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
C4X Discovery Holdings PLC
LSE:C4XD
|
Other Items
£158k
|
CAGR 3-Years
151%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Other Items
£102m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Other Items
£601k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
197%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Other Items
£5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-16%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Other Items
£3k
|
CAGR 3-Years
44%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Other Items
-£9.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
C4X Discovery Holdings PLC
Glance View
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).
See Also
What is C4X Discovery Holdings PLC's Other Items?
Other Items
158k
GBP
Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Other Items amounts to 158k GBP.
What is C4X Discovery Holdings PLC's Other Items growth rate?
Other Items CAGR 5Y
51%
Over the last year, the Other Items growth was 690%. The average annual Other Items growth rates for C4X Discovery Holdings PLC have been 151% over the past three years , 51% over the past five years .
